Stephen Basso's most recent trade in Innoviva Inc was a trade of 237 Common Stock done at an average price of $19.9 . Disclosure was reported to the exchange on Aug. 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.95 per share. | 20 Aug 2025 | 237 | 23,281 (0%) | 0% | 19.9 | 4,728 | Common Stock |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 1,353 | 23,755 (0%) | 0% | 0 | Common Stock | |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.78 per share. | 20 May 2025 | 237 | 23,518 (0%) | 0% | 18.8 | 4,451 | Common Stock |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 100,831 | 276,730 | - | - | Non-statutory Stock Option | |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 18.08 per share. | 24 Feb 2025 | 10,569 | 22,402 (0%) | 0% | 18.1 | 191,088 | Common Stock |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.07 per share. | 20 Feb 2025 | 1,106 | 11,833 (0%) | 0% | 18.1 | 19,985 | Common Stock |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 843 | 12,939 (0%) | 0% | 0 | Common Stock | |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 25,899 | 175,899 | - | - | Non-statutory Stock Option | |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 14.88 per share. | 05 Mar 2024 | 12,096 | 12,096 (0%) | 0% | 14.9 | 179,988 | Common Stock |
| Innoviva Inc | Stephen Basso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 150,000 | 150,000 | - | - | Nonqualified Stock Option | |
| Inozyme Pharma Inc | Stephen Basso | SVP Finance (PFO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Stephen Basso | SVP Finance (PFO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Stephen Basso | SVP Finance (PFO) | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 41,794 | 41,794 | - | - | Stock Option (right to buy) |